Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors
Oncogenic neurotrophic tropomyosin receptor kinase gene fusions occur in less than 1% of common cancers. These mutations have emerged as new biomarkers in cancer genomic profiling with the approval of selective drugs against tropomyosin receptor kinase fusion proteins. Nevertheless, the optimal path...
Saved in:
Main Authors: | Mariana Petaccia de Macedo (Author), Ellen Caroline Toledo Nascimento (Author), Fernando Augusto Soares (Author), Fernando Costa Santini (Author), Felipe D'Almeida Costa (Author), Isabela Werneck da Cunha (Author), Rodrigo Ramella Munhoz (Author), Pedro De Marchi (Author), Thiago William Carnier Jorge (Author), Kátia Ramos Moreira Leite (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NTRK fusions in osteosarcoma are rare and non‐functional events
by: Baptiste Ameline, et al.
Published: (2020) -
Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
by: Jeongwan Kang, et al.
Published: (2020) -
Dermoscopic Features of Spitz Tumor With LMNA-NTRK1 Fusion
by: Ben J. Friedman, et al.
Published: (2020) -
Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
by: Ruiying Zhao, et al.
Published: (2021) -
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
by: Liu D, et al.
Published: (2018)